Recent 8.2% Pullback Isn't Enough to Hurt Long-term Innovative Medical ManagementLtd (SZSE:002173) Shareholders, They're Still up 26% Over 1 Year
Recent 8.2% Pullback Isn't Enough to Hurt Long-term Innovative Medical ManagementLtd (SZSE:002173) Shareholders, They're Still up 26% Over 1 Year
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. For example, the Innovative Medical Management Co.,Ltd. (SZSE:002173) share price is up 26% in the last 1 year, clearly besting the market decline of around 11% (not including dividends). That's a solid performance by our standards! Longer term, the stock is up 24% in three years.
投資股票的最簡單方法是購買交易所交易基金。但是,您可以通過選擇高於平均水平的股票來顯著提高回報。例如,創新醫療管理公司。,Ltd.(SZSE:002173)的股價在過去1年中上漲了26%,顯然超過了約11%(不包括股息)的市場跌幅。按照我們的標準,這是一項不錯的表現!從長遠來看,該股在三年內上漲了24%。
Since the long term performance has been good but there's been a recent pullback of 8.2%, let's check if the fundamentals match the share price.
由於長期表現良好,但最近出現了8.2%的回調,讓我們來看看基本面是否與股價相符。
View our latest analysis for Innovative Medical ManagementLtd
查看我們對創新醫療管理有限公司的最新分析
Given that Innovative Medical ManagementLtd didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
鑑於Innovative Medical Medical ManagementLtd在過去十二個月中沒有盈利,我們將專注於收入增長,以快速了解其業務發展。無利可圖公司的股東通常預計收入將強勁增長。那是因爲可以很容易地推斷出快速的收入增長來預測利潤,而利潤通常規模相當大。
Innovative Medical ManagementLtd grew its revenue by 8.1% last year. That's not a very high growth rate considering it doesn't make profits. In keeping with the revenue growth, the share price gained 26% in that time. While not a huge gain tht seems pretty reasonable. Given the market doesn't seem too excited about the stock, a closer look at the financial data could pay off, if you can find indications of a stronger growth trend in the future.
去年,創新醫療管理有限公司的收入增長了8.1%。考慮到它無法獲利,這並不是一個很高的增長率。爲了與收入增長保持一致,股價在此期間上漲了26%。雖然收益不大,但這似乎很合理。鑑於市場似乎對該股並不太興奮,如果你能發現未來增長趨勢更強勁的跡象,仔細觀察財務數據可能會得到回報。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
公司的收入和收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。
You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
您可以在這張免費的交互式圖片中看到其資產負債表如何隨着時間的推移而增強(或減弱)。
A Different Perspective
不同的視角
We're pleased to report that Innovative Medical ManagementLtd shareholders have received a total shareholder return of 26% over one year. That gain is better than the annual TSR over five years, which is 3%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand Innovative Medical ManagementLtd better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Innovative Medical ManagementLtd .
我們很高興地向大家報告,Innovative Medical Medical ManagementLtd的股東在一年內獲得了26%的股東總回報率。該增幅優於五年內的年度股東總回報率,後者爲3%。因此,最近公司周圍的情緒似乎一直樂觀。持樂觀觀點的人可能會將最近股東總回報率的改善視爲業務本身隨着時間的推移而變得越來越好。從長遠來看,追蹤股價表現總是很有意思的。但是,爲了更好地了解創新醫療管理有限公司,我們需要考慮許多其他因素。爲此,你應該注意我們在Innovative Medical ManagementLtd發現的1個警告信號。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
如果你想看看另一家公司——一家財務狀況可能優異的公司——那麼千萬不要錯過這份已經證明自己可以增加收益的公司的免費名單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。